THE latest edition of Australian Prescriber from NPS MedicineWise highlights three new drugs on the Australian market.
Brexpiprazole (Rexulti from Lundbeck) is a new antipsychotic for schizophrenia, is structurally similar to aripiprazole and has a similar mechanism of action.
Somavert (pegvisomant) by Pfizer binds to growth hormone receptors and is indicated for acromegaly as a powder for reconstitution.
Thirdly, NPS writes up Gilead's Epculsa (sofosbuvir-velpatasvir fixed combination) for hepatitis C.
Visit nps.org.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Oct 17
